Thomas Aaberg Jr, MD

Aaberg is chief medical officer at Neurotech Pharmaceuticals. He is a retina specialist with Retina Specialists of Michigan, and an assistant clinical professor at Michigan State University in East Lansing.

Articles by Thomas Aaberg Jr, MD

A roadmap to preserving the prime years of patients diagnosed with MacTel

ByThomas Aaberg Jr, MD

October 18th 2022

According to Thomas Aaberg, MR, the novel therapy is geared to treat rare, debilitating eye disease.

Thomas Aaberg Jr, MD

Articles by Thomas Aaberg Jr, MD

A roadmap to preserving the prime years of patients diagnosed with MacTel

Latest Updated Articles

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Treating myopia today: US-focused treatments, challenges, and global insights

US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation

Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program